The major findings of this clinical study are (1) PTEN loss is not a major determinant of time to castration-resistance in prostate cancer in Jordan, and (2) combination/sequential ADT regimens achieve better outcomes of hormonal therapy compared to monotherapy regimens, by delaying the onset of CRPC. This evidence concerns the gene PTEN and prostate carcinoma.